Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results

Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 DiabeticsSignificance

(2015) Arman Qamar et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic ValveCLINICAL PERSPECTIVE

(2015) Rihab Bouchareb et al.   CIRCULATION

The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia

(2015) Frank M. Sacks   CURRENT OPINION IN LIPIDOLOGY

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis

(2015) Moritz C. Wyler von Ballmoos et al.   Journal of Clinical Lipidology

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)

(2015) Corey A. Scipione et al.   JOURNAL OF LIPID RESEARCH

Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis

(2015) Romain Capoulade et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

(2015) Sotirios Tsimikas et al.   LANCET

Chylomicronaemia—current diagnosis and future therapies

(2015) Amanda J. Brahm et al.   Nature Reviews Endocrinology

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

(2015) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein C-III: From Pathophysiology to Pharmacology

(2015) Giuseppe Danilo Norata et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)

(2014) Peter Willeit et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a)

(2014) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

(2014) Anders Berg Jørgensen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting APOC3 in the Familial Chylomicronemia Syndrome

(2014) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein C-III

(2013) Murray W. Huff et al.   CIRCULATION RESEARCH

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

(2013) Mark J. Graham et al.   CIRCULATION RESEARCH

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

(2013) John J.P. Kastelein et al.   Journal of Clinical Lipidology

Lipoprotein(a): resurrected by genetics

(2013) F. Kronenberg et al.   JOURNAL OF INTERNAL MEDICINE

Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population

(2013) Pia R. Kamstrup et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetic Associations with Valvular Calcification and Aortic Stenosis

(2013) George Thanassoulis et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study

(2012) Michael H. Davidson et al.   Journal of Clinical Lipidology

Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events

(2012) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apolipoprotein C‐III as a Potential Modulator of the Association Between HDL‐Cholesterol and Incident Coronary Heart Disease

(2012) Majken K. Jensen et al.   Journal of the American Heart Association

Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease

(2011) Carlos O. Mendivil et al.   CIRCULATION

Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia

(2011) Kevin C. Maki et al.   Journal of Clinical Lipidology

Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome

(2008) Dick C. Chan et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance

(2007) Herbert Schuster et al.   ATHEROSCLEROSIS